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We describe the rationale and design of the ongoing randomized, active-controlled, 
multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus 
gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 
lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, 
and who failed front-line regimens containing rituximab. The administration schedule is 
pixantrone 50 mg/m2 intravenously (iv.) or gemcitabine 1000 mg/m2 iv. on days 1, 8 and 
15, combined with rituximab 375 mg/m2 iv. on day 1, up to six cycles. Pixantrone has a 
conditional European marketing approval for monotherapy in adults with multiple relapsed 
or refractory aggressive B-cell non-Hodgkin lymphoma. Our trial explores the efficacy of 
combining pixantrone with rituximab and completes postauthorization measures. Trial 
registration number: NCT01321541.
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Pixantrone is a novel aza-anthracenedione compound with antitumor activity [1,2]. It received market-
ing approval in Europe for monotherapy in the treatment of adult patients with multiple relapsed 
or refractory aggressive non-Hodgkin lymphoma (NHL) [3], with a postauthorization marketing 
requirement. In this paper, we describe the rationale and design of the Phase III study PIX306, also 
known as PIX-R (pixantrone–rituximab vs gemcitabine–rituximab in treating relapsed/refractory 
transplant-ineligible aggressive NHL), which is intended to confirm the efficacy of pixantrone 
combined with rituximab and complete the postauthorization requirement.
Rationale
NHL is the fifth most common type of cancer with annual estimates of nearly 150,000 cases in the 
EU and the USA combined [4–6]. Aggressive NHL comprises 44% of all NHL [7], and diffuse large 
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B-cell lymphoma (DLBCL) is the most common 
subtype, accounting for 75% of all aggressive 
lymphomas.
Anthracycline-based regimens are the stand-
ard of care for front-line therapy in aggressive 
NHL and DLBCL, notably with R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisone) [8,9]. R-CHOP 
can produce good rates of durable response, 
but between 30 and 50% of patients relapse 
or prove to be refractory to initial therapy. A 
high-dose myeloablative regimen followed by 
stem cell transplant (SCT) is a potential cura-
tive option for those who can tolerate the pro-
cedure. However, a substantial proportion of 
relapsed patients do not receive SCT for a vari-
ety of reasons, such as comorbidities, advanced 
age, patient choice or failure to have a complete 
or partial response to second-line therapy [10]. 
Among patients who are not candidates for SCT, 
or who relapse following second-line regimens, 
response rates are low, complete remissions are 
rare and expected survival is <6 months. There 
is currently no standard treatment for patients 
with relapsed/refractory aggressive NHL beyond 
second-line treatment regimens [11]. Retreatment 
with anthracyclines is generally avoided because 
the risk of cardiac toxicity increases with the 
cumulative dose [12]. The lack of consensus 
regarding treatment of patients with relapsed or 
refractory aggressive NHL and the lack of robust 
data supporting current clinical practices clearly 
demonstrate the need for more controlled trials 
in this setting to define additional therapies for 
this patient population.
●● Rationale for pixantrone & rituximab in 
aggressive relapsed or refractory NHL
Pixantrone is a novel aza-anthracenedione com-
pound with a distinct chemical structure that 
confers a different toxicity profile and mechanism 
of action from anthracyclines [12]. Pixantrone 
was designed to improve efficacy and reduce the 
toxicity of anthracenediones, by increasing the 
stability of DNA adduct formation, while reduc-
ing the potential to form oxygen-free radicals 
and toxic drug–metal complexes. Pixantrone 
is a weak topoisomerase II inhibitor and forms 
stable DNA adducts through alkylation with 
specificity for DNA hypermethylated sites [13,14]. 
Moreover, pixantrone does not generate oxygen-
free radicals since it cannot bind iron, which is 
the putative mechanism for the cardiac toxicity 
of anthracycline and anthracenediones. Recent 
findings suggest that pixantrone induces a latent 
type of DNA damage that impairs the fidelity 
of mitosis, without triggering DNA damage 
response or mitotic checkpoint activation, but 
is lethal after successive rounds of aberrant divi-
sion [15]. This mechanism of cell killing appears 
to be by impairing chromosome segregation that 
generates severely aneuploid cells. The molecu-
lar mechanisms by which pixantrone impairs 
 mitosis remain to be elucidated.
The efficacy of pixantrone has been evalu-
ated in >400 patients with hematological and 
solid-tumor malignancies in single-agent or 
combination regimens. A randomized controlled 
Phase III trial with pixantrone [16] included 140 
patients with stage III–IV aggressive NHL who 
had previously received two or more lines of sys-
temic therapy (including SCT following high-
dose myeloablative therapy). Eligible patients 
were aged 18 years or older and had adequate 
organ function (notably left ventricular ejection 
fraction [LVEF]: ≥50%). They were randomly 
allocated to pixantrone dimaleate 85 mg/m2 by 
1 h intravenous (iv.) infusion on days 1, 8 and 
15 of each 28-day cycle for up to six cycles, or to 
physician’s choice of the single-agent compara-
tor drug most appropriate for that patient using 
prespecified standard doses and schedules. The 
pixantrone dimaleate dosage of 85 mg/m2 used 
in the study is equivalent to 50 mg/m2 in the 
currently approved base expression. The com-
parator was physician’s choice of treatment, and 
vinorelbine, oxaliplatin, ifosfamide, etoposide, 
mitoxantrone and gemcitabine were adminis-
tered. As the trial took place before rituximab 
was standard of care, only 54% of patients had 
previously received rituximab. Treatment with 
pixantrone was associated with better rates of 
complete (or unconfirmed complete) response 
(24.3 vs 7.1% for comparator at the end of 
study; p = 0.009) [16]. Objective response rates 
(ORR) were also in favor of pixantrone (40.0 
vs 14.3% for comparator; p = 0.001), as was 
median progression- free survival (PFS; 5.3 vs 
2.6 months; hazard ratio [HR]: 0.60; p = 0.005) 
and median overall survival (OS; 10.2 vs 
7.6 months; HR: 0.79; p = 0.25).
The Phase III study also confirmed the safety 
profile of pixantrone. The most common grade 
3 or 4 adverse events were neutropenia (41.2 vs 
19.4% with comparator), leukopenia (23.5 vs 
7.5%) and thrombocytopenia (11.8 vs 10.4%), 
all of which were manageable [16]. Although the 
frequency of cardiac events was higher in the 
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pixantrone group, these were predominantly 
asymptomatic grade 1 and 2 declines in LVEF. 
This may have been related to the fact that more 
pixantrone patients had a history of cardiac dis-
ease at baseline (three patients with a history of 
congestive heart failure and two patients with 
cardiomyopathy, versus none in the comparator 
group). Other adverse events reported in the 
global safety analysis of pixantrone [17] include 
anemia (31%), asthenia (23%), pyrexia (23%), 
cough (22%), decreased LVEF (19%) and nau-
sea (18%). Treatment with pixantrone is also 
associated with a reversible blue skin discolora-
tion in about 10% of patients. The safety of pix-
antrone in NHL has also been explored in vari-
ous combination therapies with no unexpected 
adverse events [17]. Pixantrone is indicated in 
the treatment of relapsed and refractory aggres-
sive NHL with a postauthorization requirement 
for more evidence of the value of pixantrone in 
combination with rituximab.
Rituximab is a genetically engineered chi-
meric mouse/human monoclonal antibody that 
binds to the transmembrane antigen CD20. 
Rituximab is the foundation of treatment regi-
mens in CD20-positive NHL, and has been 
evaluated in the treatment of patients with 
relapsing or refractory aggressive lymphoma [18–
20], with good results, including a median time 
to progression that exceeded 240 days. The dos-
ing schedule in NHL is 375 mg/m2 iv. on day 1 
of a 28-day cycle. Treatment with rituximab is 
well-tolerated, and the most frequently reported 
adverse events are mild and related to infusion 
syndrome.
Combining pixantrone chemotherapy with 
the anti-CD20 agent rituximab is expected 
to produce synergistic effects with minimal 
overlapping toxicity and minimal drug inter-
actions. Although single-agent rituximab has 
only modest activity in patients with aggressive 
NHL who have had prior rituximab therapy, 
it may have an additive or synergistic activ-
ity with an active agent such as pixantrone 
or gemcitabine in a combination setting [21]. 
Indeed, the potential benefit of added efficacy 
outweighs the risks of combining these agents 
in a setting for which there is no standard 
therapy. Pixantrone is excreted predominantly 
unchanged by the liver, whereas rituximab is 
a humanized monoclonal antibody with no 
known effects on hepatic excretory function. 
The likelihood of a p harmacokinetic interaction 
is therefore extremely low.
●● Rationale for gemcitabine & rituximab in 
aggressive relapsed or refractory NHL
There is currently no established standard of care 
for the treatment of patients with relapsed or 
refractory DLBCL who are not candidates for 
SCT. Patients may be ineligible for transplant 
due to failure to respond to a standard salvage 
regimen, advanced age, toxicity from prior 
t herapies or serious comorbidities.
Gemcitabine has activity as a single agent in 
lymphoma [22], and a synergy with rituximab 
has been reported in preclinical studies in lym-
phoma models. The choice of comparator was 
based on the National Comprehensive Cancer 
Network guidelines published at the time for 
patients with relapsed/refractory DLBCL who 
are not candidates for SCT [23], recommending 
entry to a clinical study, or single-agent, doublet, 
or multiagent regimens, some containing gem-
citabine and/or rituximab. This is also supported 
in a study by Wenger et al. [24], which showed a 
72% response rate for the combination of gem-
citabine plus rituximab in a very limited num-
ber of patients. In relapsed or refractory DLBCL 
patients, the rate of complete response (CR) was 
20%. This aligns with rates of 20–50% reported 
with other regimens.
Once they reach third-line treatment, nearly 
all patients will have been exposed to R-CHOP. 
There is no standard of care regimen beyond 
second-line therapy, and active drugs include 
pixantrone, gemcitabine, cisplatin, cytarabine 
and bendamustine. Gemcitabine is a nucleoside 
analog with broad antitumor activity in ovar-
ian, breast, non-small-cell lung and pancreatic 
cancer [25,26], particularly in combination with 
chemotherapy. The most commonly used dosing 
schedules are 1000 mg/m2 iv. infusion on days 1 
and 8 of a 21-day cycle (ovarian cancer or breast 
cancer) and 1000 mg/m2 on days 1, 8 and 15 of 
a 28-day cycle (lung and pancreatic cancer) [26]. 
The agent has a good safety profile, and the most 
common adverse effects are hematological toxici-
ties. Other adverse effects are cutaneous rash, flu-
like symptoms, edema and pulmonary t oxicities, 
as well as nausea, vomiting and diarrhea.
Gemcitabine has been evaluated in patients 
with relapsed or refractory lymphoma [27–29], 
and has shown promising activity in heavily pre-
treated patients, even those who have progressed 
after SCT [30], with ORRs that are generally 
about 20% [22,24]. Its favorable toxicity profile 
implies that it can be safely combined with anti-
CD20 therapies, and no cross-resistance with 
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other nucleoside analogs has been reported. 
Preclinical studies suggest that the use of a 
combination of gemcitabine with rituximab in 
lymphoma is associated with significant tumor 
growth inhibition [31]. The combination of 
gemcitabine and rituximab therefore appears as 
a reasonable therapeutic option in patients with 
relapsed NHL if they are ineligible for SCT. 
Both gemcitabine and rituximab have demon-
strable activity against DLBCL in monotherapy, 
with approximately 20 and 30% ORRs, respec-
tively. We therefore selected the combination of 
gemcitabine and rituximab for the comparator 
group of our study.
Study design
We designed a randomized, active-controlled, 
multicenter, Phase III study to evaluate the effi-
cacy of pixantrone plus rituximab versus gemcit-
abine plus rituximab in patients with aggressive 
B-cell NHL. The study is being conducted in 
North America and Europe.
The target population is relapsed or refractory 
patients aged ≥18 years with either DLBCL or 
follicular grade 3 lymphoma (3a or 3b; tissue 
biopsy). Selected inclusion and exclusion criteria 
are presented in Box 1. All patients must have 
relapsed after at least one multiagent chemo-
therapy containing rituximab. De novo DLBCL 
patients and patients with follicular grade 3 
lymphoma must have received one to three prior 
regimens, while those DLBCL transformed from 
indolent lymphoma must have received one to 
four prior regimens for NHL. Patients with 
primary refractory NHL were excluded. They 
should be currently ineligible for high-dose 
therapy or SCT, according to investigator’s 
opinion. Patients not eligible for SCT could 
include those who relapsed after previous SCT, 
did not respond to a standard salvage regimen, 
did not mobilize an adequate number of stem 
cells for SCT or are unsuitable for SCT due to 
other medical conditions, age, patient choice, 
financial constraints or other reasons. Included 
patients also had to have performance status of 
Eastern Cooperative Oncology Group score ≤2, 
normal cardiac function (LVEF ≥45% and nor-
mal serum troponin T) and all acute toxicities 
to prior treatment recovered to at least grade 1 
(with the exception of alopecia).
Treatment plan
The study design is presented in Figure 1. Patients 
are being randomly allocated (1:1) to one of two 
treatment groups with up to six cycles of 28 days 
each. In the investigational therapy arm, patients 
receive pixantrone 50 mg/m2 iv. on days 1, 8 
and 15 of each cycle plus rituximab 375 mg/m2 
iv. on day 1. Patients in the control arm receive 
gemcitabine 1000 mg/m2 iv. on days 1, 8 and 15 
of each cycle plus rituximab 375 mg/m2 iv. on 
day 1. Investigators are requested to administer 
rituximab prior to the cytotoxic agent on day 1. 
Preparation of all study drugs and storage and 
handling follows the corresponding package 
inserts.
Randomization is performed using an elec-
tronic data capture system, and stratified by 
number of prior therapies for DLBCL or follicu-
lar grade 3 lymphoma (0–2 vs ≥3), International 
Prognostic Index (IPI; 0–2 vs ≥3), and length 
of time from initiation of first-line therapy for 
DLBCL or follicular grade 3 lymphoma until 
first relapse (<1 vs ≥1 year). Treatment assign-
ment is known to investigators and patients, 
though the sponsor will remain blinded during 
the study.
Patients who discontinue pixantrone, gemcit-
abine or rituximab for toxicity may remain in the 
study on monotherapy with the other study treat-
ment for up to six cycles. A single dose reduction 
in pixantrone (to 41 mg/m2) is permitted due 
to toxicities during the study. Up to two dose 
reductions for gemcitabine are allowed, with the 
first reduction to 750 mg/m2 and the second to 
500 mg/m2. Patients who complete six cycles 
of treatment or discontinue treatment for any 
reason enter a 6-month early follow-up period, 
followed by an 18-month intermediate follow-up 
for the purposes of evaluating disease response 
(Figure 1). At the time patients experience progres-
sive disease, begin subsequent anticancer therapy 
(except for rituximab given as maintenance ther-
apy) or withdraw consent for study procedures, 
they enter the survival follow-up period.
Patients may receive all concomitant treat-
ments deemed necessary to provide adequate 
support, including antiemetics, medications to 
prevent or treat rituximab hypersensitivity and 
medications to prevent tumor lysis syndrome. 
Colony-stimulating factors may be used at the 
investigator’s discretion, but must be discontin-
ued at least 2 days prior to study drug admin-
istration (and only after day 15 of each cycle 
in the case of pegfilgrastim). Photosensitivity 
is a potential clinical risk of pixantrone and so 
patients are advised to avoid sun exposure or use 
a sunscreen that absorbs UVA radiation.
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Patients receiving CYP1A2 substrates con-
comitant to pixantrone should be closely moni-
tored, notably for theophylline levels, and coagu-
lation should be monitored in those receiving 
warfarin. Blood counts should be closely moni-
tored when pixantrone is coadministered with 
agents that inhibit membrane transport proteins 
Pgp/BRCP and OCT1, such as cyclosporine A or 
tacrolimus, and anti-HIV agents (e.g., ritonavir, 
saquinavir and nelfinavir). In addition, caution 
should be applied when pixantrone is continu-
ously coadministered with eff lux transport 
inducers (e.g., rifampicin, carbamazepine and 
glucocorticoids).
End points
The primary and secondary end points are listed 
in Box 2. PFS was selected as the primary end 
Box 1. Selected inclusion and exclusion criteria.
Inclusion criteria
 ●  Age ≥18 years old
 ●  Documented de novo DLBCL, DLBCL transformed from indolent lymphoma or follicular grade 3 lymphoma on the basis of a tissue biopsy
 ●  Previous therapies: one to three prior regimens for patients with de novo DLBCL or follicular grade 3 lymphoma; one to four prior regimens 
for patient with DLBCL transformed from indolent lymphoma
 ●  Prior treatment with a rituximab-containing multiagent regimen
 ●  For patients with DLBCL transformed from indolent lymphoma, previous complete or partial response to therapy for ≥12 weeks
 ●  Not eligible for high-dose (myeloablative) chemotherapy and SCT (i.e., relapsed after SCT, no response to standard salvage regimen, 
inadequate number of cells for SCT or unsuitable for SCT due to other medical conditions, age, personal preference, financial constraints or 
other reasons)
 ●  At least 28 days from completion of last therapy to randomization
 ●  At least one bidimensionally measurable site of disease that has not been previously irradiated: nodal disease ≥1.5 cm in short axis or 
extranodal disease >1.0 cm in short axis
 ●  ECOG performance status ≤2
 ●  Life expectancy ≥12 weeks in investigator’s judgment
 ●  LVEF ≥45% and normal serum troponin T
 ●  Hemoglobin ≥8 g/dl, platelet count ≥100 × 109/l (≥75 × 109/l if documented bone marrow involvement), ANC ≥1.5 × 109/l (≥1.0 × 109/l if 
documented bone marrow involvement), serum bilirubin ≤1.5 × ULN (≤5 × ULN in patients with Gilbert’s syndrome), AST and ALT ≤2 × ULN 
(≤5 × ULN if elevation is due to hepatic involvement by lymphoma), serum creatinine ≤2 × ULN
 ●  All acute toxicities related to prior treatment recovered to grade ≤1, except alopecia
 ●  Written informed consent
 ●  Effective birth control
Exclusion criteria
 ●  Any of the following as the only site(s) of disease: palpable lymph nodes not visible on imaging studies, skin lesions or bone marrow 
involvement only
 ●  Primary refractory de novo DLBCL or primary refractory follicular grade 3 lymphoma, defined as documented progression within 12 weeks 
of the last cycle of the first-line multiagent regimen
 ●  Prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 450 mg/m2
 ●  Active grade 3/4 infection (National Cancer Institute Common Terminology Criteria for Adverse Events)
 ●  Major surgery ≤28 days prior to randomization
 ●  Known acute or chronic hepatitis B or hepatitis C virus infection or HIV
 ●  Current CNS involvement by lymphoma
 ●  Any experimental therapy ≤28 days prior to randomization
 ●  Myocardial infarction in the past 6 months
 ●  New York Heart Association class III or IV heart disease
 ●  Other malignancy in the last 5 years (except curatively treated basal cell/squamous cell skin cancer, carcinoma in situ of the cervix, 
superficial transitional cell bladder carcinoma, in situ ductal carcinoma of the breast after complete resection, localized, resected and/or 
low-risk prostate cancer)
 ●  Any contraindication, known allergy or hypersensitivity to any of the study drugs
 ●  Pregnant or lactating
 ●  Concomitant therapy with any anticancer agents, immunosuppressive agents or other investigational anticancer therapies
ALT: Alanine aminotransferase; ANC: Absolute neutrophil count; AST: Aspartate aminotransferase; DLBCL: Diffuse large B-cell lymphoma; ECOG: Eastern Cooperative Oncology 
Group; LVEF: Left ventricular ejection fraction; SCT: Stem cell transplant; ULN: Upper limit of normal.
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point since it reflects the effect of therapy on 
tumor growth and is not confounded by subse-
quent systemic anticancer therapy. PFS is defined 
as time from randomization to disease progres-
sion or death due to any cause (whichever occurs 
first). It is therefore considered as a surrogate for 
OS (i.e., time from randomization until death 
due to any cause), which is a secondary end 
point. Response is also recorded as a secondary 
end point according to international criteria [32] 
and reported as CR (the proportion of patients 
who achieve CR without subsequent systemic 
anticancer therapy, except for rituximab given 
as maintenance therapy) and ORR (the pro-
portion of patients who achieve CR or partial 
response without additional therapy). Safety is 
also assessed, including adverse events and labo-
ratory values, with a particular focus on grade 3 
and 4 adverse events, treatment-related adverse 
events, adverse events leading to treatment dis-
continuation or death, and cardiotoxicity as 
measured by echocardiography and troponin T. 
Exploratory end points include duration of com-
plete and overall responses and proportion of 
patients receiving SCT after therapy.
Efficacy & safety evaluations
Demographics and baseline disease characteris-
tics are collected at the screening visit, together 
with a physical examination, vital signs, bod-
yweight, medical and cardiac history and a 
detailed history of primary NHL diagnosis and 
all prior treatments for NHL. The sponsor or 
designated CRO reviews the pathology and 
immunohistochemistry reports documenting a 
current histological diagnosis to confirm patient 
eligibility. Prior tissue biopsy slides confirming 
follicular grade 3 lymphoma or DLBCL must be 
available at screening to be submitted for central 
pathology review. If a bone marrow biopsy has 
been performed at the investigator’s initiative 
within 8 weeks of randomization, the results of 
the local review must be provided.
Disease assessment includes neck, chest, abdo-
men and pelvis via CT scan with iv. contrast, 
if possible, or else MRI of the neck, abdomen 
and pelvis with noncontrast chest CT scan. 
The imaging method used for each partici-
pant at baseline is used throughout the study. 
The assessment is carried out at baseline and 
performed at 8, 16, 24, 36, 48, 60, 72, 84 and 
Figure 1. Study design.  
†Any patient who develops progressive disease or relapses during treatment or in early or intermediate follow-up, begins 
nonprotocol-directed non-Hodgkin lymphoma therapy or withdraws consent for treatment and enters the survival follow-up period. 
‡Stratification according to time to first relapse (<1 or ≥1 year), International Prognostic Index (0–2 vs ≥3), and number of prior regimens 
(0–2 or ≥3).
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96 weeks. Baseline PET is not required except 
at the end of study visit. A bone marrow biopsy 
with core is required at end of treatment to con-
firm a CR, unless a bone marrow biopsy was 
obtained at baseline and was negative.
The safety assessment includes a complete 
chemistry panel (total bilirubin, alkaline phos-
phatase, ALT, AST, total protein, albumin, 
sodium, potassium, calcium, magnesium, phos-
phorous, glucose, creatinine, lactate dehydro-
genase and uric acid); record of bodyweight, 
Eastern Cooperative Oncology Group perfor-
mance status and complete blood count dif-
ferential at baseline and at day 1 of each cycle. 
Urinalysis is performed only at baseline. A 
pregnancy test is performed on day 1 of each 
cycle for women with childbearing age during 
the treatment period. All laboratory test values 
are evaluated both locally and centrally, though 
local evaluations are used for decisions regarding 
study eligibility and clinical emergencies.
Cardiac assessment comprises LVEF by 
echocardiogram, ECG and serum troponin T 
at baseline and at end of treatment. LVEF and 
serum troponin T are performed at cycles 3 and 
5, and at follow-up at 6 months.
An Independent Radiological Committee 
(IRC) assesses radiographic images based on 
a prespecified Image Charter, and response 
to treatment is evaluated using the Modified 
IWG Revised Response Criteria for Malignant 
Lymphoma [32]. Measurable sites of disease are 
defined as clearly bidimensionally measurable 
lymph nodes or nodal masses (≥1.5 cm in short 
axes) and extranodal sites (>1.0 cm in short axes) 
of lymphoma. One to six bidimensionally meas-
urable nodal or extranodal sites of disease are 
selected at baseline as target lesions. Measurable 
lesions representative of all affected organs should 
be included; if measurable nodal disease is pre-
sent in the mediastinum or retroperitoneum, at 
least one lesion from that region is included as a 
target lesion. Measurable lesions in a previously 
radiated site cannot be considered target lesions.
Statistical considerations
Sample size calculations indicate that 195 pri-
mary PFS events are required to detect ≥35% 
improvement in PFS with 85% power and a two-
sided α of 0.05. The median PFS in the control 
group is assumed to be 2.8 months. On the basis 
of enrollment projections, it is estimated that 
260 patients will need to be enrolled to reach 
the required 195 PFS events. For the secondary 
end point of OS, 220 deaths are planned to be 
sufficient to have 75% power to detect ≥30% 
improvement in OS allowing for 5% drop-offs, 
or 68% power to detect ≥28% improvement in 
OS. The median OS for the control group is 
assumed to be 7 months, according to a p revious 
study [16].
The main efficacy analyses will be performed 
in the intention-to-treat population (i.e., all ran-
domized patients). Analyses will also be per-
formed in the histologically confirmed popula-
tion (i.e., all randomized patients with DLBCL 
or follicular grade 3 lymphoma confirmed by 
central pathology review) and the per proto-
col population (all randomized patients who 
undergo at least one postbaseline disease assess-
ment and have no major protocol violations). 
Sensitivity analyses will be performed to evaluate 
the robustness of the PFS result.
Treatment effect will be compared using a 
log-rank test stratified by IPI score, prior lines of 
therapy and length of time between first therapy 
and first relapse. The Kaplan–Meier product-limit 
method will be used to estimate the distribution of 
PFS. The primary end point analysis will be per-
formed after 195 events have occurred. The final 
analysis for OS (end of study) will be performed 
after 220 OS events. All statistical  analyses will 
be performed by CTI Biopharma Corp.
Other subgroup analyses will be performed 
as appropriate and will include the number of 
prior treatment regimens for DLBCL and fol-
licular grade 3 lymphoma, length of time from 
initiation of therapy for DLBCL or follicular 
grade 3 lymphoma until first relapse, and IPI 
score. Safety will be assessed in all randomized 
patients who take at least one dose of study drug.
Box 2. Primary and secondary end points.
Primary end point
 ●  Progression-free survival
Secondary end points
 ●  Overall survival
 ●  Overall response rate
 ●  Complete response rate
 ●  Safety
Exploratory end points
 ●  Duration of overall response
 ●  Duration of complete response
 ●  Proportion of patients receiving stem cell 
transplant after study treatment
All end points will be compared between patients receiving 
pixantrone plus rituximab and those receiving gemcitabine 
plus rituximab.
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Study organization
The study is being conducted in accordance with 
the International Conference on Harmonisation 
principles of Good Clinical Practice and the 
Declaration of Helsinki (1989), as well as all 
national, state and local laws of the applicable 
regulatory agencies. The trial is registered on 
ClinicalTrials.gov: NCT01321541.
A number of independent trial committees have 
been set up to oversee the conduct of the study. 
The Independent Data Monitoring Committee 
(IDMC) meets every 6 months or after 30 addi-
tional patients are randomized, whichever occurs 
first. The IDMC’s responsibilities include: mini-
mizing exposure of patients to unsafe therapies 
or doses; evaluating toxicity and appropriateness 
of doses and recommending design amendments 
if appropriate; and advising on the need for dose 
adjustments or assessments due to safety issues.
The IRC will determine the disease responses. 
The IRC will be blinded to site identifiers, patient 
treatment arm and investigator’s designation of 
target lesions. All radiographic images will be 
read by two radiologists, and any disagreement 
will be adjudicated by a third radiologist. The 
final disease response assessment determined 
at each imaging evaluation will be determined 
by an independent oncologist and one of the 
radiologists who evaluate each patient’s clini-
cal, pathologic and radiologic data. Similarly, 
a Central Pathology Review Committee will 
evaluate biopsy specimens from all randomized 
patients to confirm the histological diagnosis. 
Pathology tissue and images will be read by two 
pathologists and any disagreement will be adju-
dicated by a third. Bone marrow biopsies (with 
cores) obtained during the study will undergo 
local pathology review to confirm a CR.
Conclusion
PIX-R is a randomized, active-controlled, mul-
ticenter, Phase III study evaluating the efficacy 
of pixantrone and rituximab versus gemcitabine 
and rituximab in patients with aggressive B-cell 
NHL. The trial has been designed to confirm 
the efficacy and safety of pixantrone in com-
bination with rituximab. This is an important 
study insofar as there is currently no standard 
EXECUTiVE SUMMaRY
Background
 ●  Pixantrone is a novel aza-anthracenedione compound with antitumor activity.
 ●  Pixantrone currently has conditional marketing approval in Europe for monotherapy in the treatment of adult patients 
with multiple relapsed or refractory aggressive non-Hodgkin lymphoma.
 ●  The PIX-R study has been set up to confirm the clinical efficacy observed in previous Phase III studies and complete the 
postauthorization measures.
Study rationale
 ●  There is no standard of care in non-Hodgkin lymphoma patients who relapse or who are refractory of standard 
front-line therapy, or in those who are not eligible for stem cell transplantation.
 ●  Monotherapy with pixantrone is known to be efficacious and safe in patients with relapsed or refractory aggressive 
B-cell non-Hodgkin lymphoma compared with physician’s choice of treatment.
 ●  Combining pixantrone and rituximab is expected to be effective in such patients, with a likelihood of additive or 
synergistic effects, minimal overlapping toxicity and minimal drug interactions.
Study design
 ●  PIX-R is a randomized, active-controlled, multicenter, Phase III study set up to evaluate the efficacy of pixantrone plus 
rituximab versus gemcitabine plus rituximab in patients with aggressive B-cell non-Hodgkin lymphoma.
 ●  The target population is patients with either diffuse large B-cell lymphoma (de novo or transformed from indolent 
lymphoma) or follicular grade 3 lymphoma on the basis of a tissue biopsy, who are currently ineligible for high-dose 
(myeloablative) chemotherapy and stem cell transplantation, and who relapsed after at least one multiagent 
chemotherapy containing rituximab.
 ●  The dosing schedule is pixantrone 50 mg/m2 intravenously (iv.) or gemcitabine 1000 mg/m2 iv. on days 1, 8 and 15, 
combined with rituximab 375 mg/m2 iv. on day 1 in all patients for up to six cycles.
 ●  Recruitment in PIX-R is ongoing.
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of care in this population. Recruitment in the 
trial is ongoing.
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